This site is intended for healthcare professionals
News

FDA accepts BLA for fixed-dose combination of Perjeta + Herceptin with hyaluronidase, by subcutaneous injection in combination with I.V. chemotherapy for the treatment of HER2-positive breast cancer. Genentech/Roche

Read time: 1 mins
Published:28th Feb 2020
Condition: Breast Cancer HER2+
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest